2016
Concurrent chemoradiotherapy versus radiotherapy alone for “biopsy‐only” glioblastoma multiforme
Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB. Concurrent chemoradiotherapy versus radiotherapy alone for “biopsy‐only” glioblastoma multiforme. Cancer 2016, 122: 2364-2370. PMID: 27172136, DOI: 10.1002/cncr.30063.Peer-Reviewed Original ResearchConceptsPropensity score-matched analysisConcurrent chemoradiotherapySignificant OS benefitOverall survivalGlioblastoma multiformeOS benefitUS National Cancer Data BaseMultivariable Cox proportional hazards regressionNational Cancer Data BaseCox proportional hazards regressionImproved overall survivalStandard postoperative therapyProportional hazards regressionMultivariable logistic regressionLog-rank testStandard of careChi-square testClinicopathologic predictorsPostoperative therapySurgical resectionImproved survivalMedian ageMultivariable analysisHazards regressionNational cohort
2015
Survival Benefit of Concurrent Chemoradiation Therapy for Unresected Glioblastoma Multiforme in the Temozolomide Era
Kole A, Yeboa D, Rutter C, Lester-Coll N, Corso C, Mancini B, Bindra R, Yu J, Park H. Survival Benefit of Concurrent Chemoradiation Therapy for Unresected Glioblastoma Multiforme in the Temozolomide Era. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e64. DOI: 10.1016/j.ijrobp.2015.07.706.Peer-Reviewed Original ResearchConcurrent chemoradiation therapyChemoradiation therapySurvival benefitTemozolomide eraGlioblastoma multiforme